KemPharm (NASDAQ:KMPH) Releases Earnings Results

KemPharm (NASDAQ:KMPH) issued its earnings results on Wednesday. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, MarketWatch Earnings reports.

Shares of KMPH stock traded up $0.08 during mid-day trading on Friday, hitting $0.59. The company’s stock had a trading volume of 2,129,722 shares, compared to its average volume of 2,213,248. The company’s fifty day simple moving average is $0.32 and its 200-day simple moving average is $0.28. KemPharm has a 52 week low of $0.12 and a 52 week high of $1.11. The company has a market cap of $27.29 million, a PE ratio of -1.04 and a beta of 1.60.

KMPH has been the subject of a number of research reports. Zacks Investment Research upgraded KemPharm from a “sell” rating to a “hold” rating in a research note on Wednesday, July 22nd. ValuEngine raised KemPharm from a “hold” rating to a “buy” rating in a research report on Friday, April 17th. Finally, HC Wainwright lowered their target price on KemPharm from $2.50 to $1.50 and set a “buy” rating for the company in a research report on Wednesday, May 20th.

KemPharm Company Profile

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.

Featured Story: S&P/ASX 200 Index

Earnings History for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.